Affordable Access

deepdyve-link
Publisher Website

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors
  • Younes, Anas1
  • Gopal, Ajay K
  • Smith, Scott E
  • Ansell, Stephen M
  • Rosenblatt, Joseph D
  • Savage, Kerry J
  • Ramchandren, Radhakrishnan
  • Bartlett, Nancy L
  • Cheson, Bruce D
  • de Vos, Sven
  • Forero-Torres, Andres
  • Moskowitz, Craig H
  • Connors, Joseph M
  • Engert, Andreas
  • Larsen, Emily K
  • Kennedy, Dana A
  • Sievers, Eric L
  • Chen, Robert
  • 1 The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. [email protected]
Type
Published Article
Journal
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology
Publication Date
Jun 20, 2012
Volume
30
Issue
18
Pages
2183–2189
Identifiers
DOI: 10.1200/JCO.2011.38.0410
PMID: 22454421
Source
Medline
License
Unknown

Abstract

The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after auto-SCT. Durable CRs approaching 2 years were observed, supporting study in earlier lines of therapy.

Report this publication

Statistics

Seen <100 times